No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
MURA Mural Oncology
- 3.360
- +0.010+0.30%
Close May 31 16:00 ET
- 3.440
- +0.080+2.38%
Post 19:36 ET
56.86MMarket Cap-296P/E (TTM)
3.480High3.330Low132.29KVolume3.390Open3.350Pre Close445.64KTurnover0.87%Turnover RatioLossP/E (Static)16.92MShares57.20052wk High0.24P/B51.29MFloat Cap3.23052wk Low--Dividend TTM15.26MShs Float57.200Historical High--Div YieldTTM4.48%Amplitude3.230Historical Low3.368Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | Mural Oncology Shares Data From ARTISTRY-3 Trial Designed To Evaluate Effects Of Less Frequent Intravenous Dosing Of Nemvaleukin Alfa In Advance Of ASCO Annual Meeting
Mural Oncology Presents Clinical Data From ARTISTRY-3 at the American Society of Clinical Oncology Annual Meeting
ARTISTRY-3 trial is being conducted to evaluate less frequent dosing of nemvaleukin alfa, Mural's late-stage lead candidate Nemvaleukin demonstrated pharmacodynamic proof of mechanism in ARTISTRY-3 and was generally
Mural Oncology | 10-Q: Quarterly report
Express News | Mural Oncology PLC Qtrly Shr Loss $1.84
Mural Oncology 1Q Research and Development Expenses $26.9M >MURA
Mural Oncology 1Q Research and Development Expenses $26.9M >MURA
Express News | Mural Oncology PLC: Reiterates Cash Runway Projection Into 4Q 2025, With Sufficient Capital to Fund Key Clinical Readouts
Comments
$Mural Oncology(MURA.US$
NEWS
Mural Oncology Presents Clinical Data from ARTISTRY-3 at the American Society of Clinical Oncology Annual Meeting
Mural Oncology presented data from its ARTISTRY-3 trial at the ASCO annual meeting, showing that less frequent dosing of nemvaleukin alfa (nemvaleukin), an engineered IL-2 cytokine, is well-tolerated and effective.
The trial shifted from five daily infusions to two infusions per three-week cycle, both as a single agent and in combination with pembrolizu...
NEWS
Mural Oncology Presents Clinical Data from ARTISTRY-3 at the American Society of Clinical Oncology Annual Meeting
Mural Oncology presented data from its ARTISTRY-3 trial at the ASCO annual meeting, showing that less frequent dosing of nemvaleukin alfa (nemvaleukin), an engineered IL-2 cytokine, is well-tolerated and effective.
The trial shifted from five daily infusions to two infusions per three-week cycle, both as a single agent and in combination with pembrolizu...
1
$Mural Oncology(MURA.US$
NEWS
Mural Oncology Presents Preclinical Data for IL-18 and IL-12 Programs at the 2024 American Association for Cancer Research Annual Meeting
NEWS
Mural Oncology Presents Preclinical Data for IL-18 and IL-12 Programs at the 2024 American Association for Cancer Research Annual Meeting
$Mural Oncology(MURA.US$ how do you circuit-break on 30cents,.
3
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg